Antibiotics don't benefit deadly lung-scarring disease, large trial finds (IMAGE)

University of Virginia Health System

Antibiotics don't benefit deadly lung-scarring disease, large trial finds

Caption

Imre Noth, MD, the chief of UVA Health's Division of Pulmonary and Critical Care Medicine, says the large study of idiopathic pulmonary fibrosis will still benefit efforts to battle the lung-scarring disease.

Credit

UVA Health

Usage Restrictions

May be used to accompany news coverage of the IPF trial results. All other uses require express written permission from UVA Health.

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.